gms | German Medical Science

129. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

24.04. - 27.04.2012, Berlin

Novel Bio-Artificial Pancreas Providing Immune Protection and Oxygen Supply

Meeting Abstract

  • Stefan Ludwig - Universitätsklinikum Carl Gustav Carus, Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden
  • Barbara Ludwig - Universitätsklinikum Carl Gustav Carus, Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden
  • Baruch Zimerman - Beta O2 Technologies Ltd., Petach-Tikva
  • Anja Steffen - Universitätsklinikum Carl Gustav Carus, Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden
  • Zohar Gentler - Beta O2 Technologies Ltd., Petach-Tikva
  • Stefan R. Bornstein - Universitätsklinikum Carl Gustav Carus, Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden
  • Hans-Detlev Saeger - Universitätsklinikum Carl Gustav Carus, Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden

Deutsche Gesellschaft für Chirurgie. 129. Kongress der Deutschen Gesellschaft für Chirurgie. Berlin, 24.-27.04.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgch066

DOI: 10.3205/12dgch066, URN: urn:nbn:de:0183-12dgch0661

Veröffentlicht: 23. April 2012

© 2012 Ludwig et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction: In the early post-transplant period, transplanted islets are affected by inflammatory reactions and hypoxia. Additionally, immunosuppressors are associated with islet toxicity and significant morbidity in the patient. Thus, strategies to promote islet engraftment and immune-tolerance are the moving-spirit for the proposed study: Utilization of a specially engineered macrochamber that provides complete immuno-isolation of islet grafts and allows for controlled oxygen supply.

Materials and methods: Isolated rat islets were macro-encapsulated and transplanted subcutaneously into STZ-induced diabetic rats. Oxygen supply was provided by daily s.c.-refuelling during follow-up of 90 days. The model was carried out in a syngeneic and allogeneic setting.

The model was then translated to large animals using minipigs as recipients of allogeneic and xenogeneic encapsulated islets. To test for biocompatibility and graft survival, healthy pigs were implanted with islet-containing devices. After 4 weeks the devices were explanted and assessed for viability and function. In first pre-clinical experiments, the device was tested in pancreatectomized diabetic minipigs.

Results: All transplanted rats showed normalization of blood glucose independent of syn- or allogeneic setting. After retrieval, the animals quickly reverted to hyperglycaemia. Explanted islets were morphologically and functionally intact. In the large animal model, biocompatibility of the device could be proven by absence of local inflammation or fibrosis. Retrieved islets were found intact and functional. Diabetic minipigs showed immediate and sustained normoglycemia following device implantation.

Conclusion: We have demonstrated successful application of an oxygen-refuelling macrochamber for sustained islet function and immuno-protection in rodent and large animal diabetes-models. This work opens up avenues for porcine islet xenotransplantation.